Perhaps most importantly, MT-802 retained the ability to reduce the level of the active autophosphorylated form (i.e. BTK kinase activity) of BTK in patient-derived CLL cells from an ibrutinib-resistant patient with Cys481Ser mutated BTK. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.